AGAVE-201 Data on Refractory cGvHD

Opinion
Video

In this expert analysis of the AGAVE-201 trial data, the efficacy of a monoclonal antibody in treating graft versus host disease is discussed, with the lowest dose of 0.3 mg/kg administered every 2 weeks demonstrating the highest response rates, exceeding 75%.

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
Related Content
Outcomes With Luspatercept Not Affected by Mutational Profile in MDS

Outcomes With Luspatercept Not Affected by Mutational Profile in MDS

Targeted Oncology Staff
July 7th 2025
Article

During a live event, Thomas LeBlanc, MD, MA, discussed dose escalation of luspatercept in myelodysplastic syndromes and response to treatment based on mutational analyses.

Read More

Phase 1 Trial of JBZ-001 Targets Solid Tumors and Non-Hodgkin Lymphoma

Phase 1 Trial of JBZ-001 Targets Solid Tumors and Non-Hodgkin Lymphoma

Jordyn Sava
July 4th 2025
Article

Read More

Exploring Factors Supporting TKI Discontinuation in Patients With Ph+ ALL

Exploring Factors Supporting TKI Discontinuation in Patients With Ph+ ALL

Martina Canichella, MD, PhD;Elisabetta Abruzzese, MD, PhD
June 27th 2025
Article

Recent studies reveal promising outcomes for discontinuing TKI therapy in select patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, suggesting potential long-term remission.

Read More

Luspatercept Outperforms ESA in Duration of Anemia Response in MDS

Luspatercept Outperforms ESA in Duration of Anemia Response in MDS

Targeted Oncology Staff
June 24th 2025
Article

During a live event, Thomas LeBlanc, MD, MA, discussed the outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndromes.

Read More

FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML

FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML

Jordyn Sava
June 19th 2025
Article

SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited treatment options.

Read More

Tagraxofusp Yields Deep Responses as Frontline BPDCN Therapy

Tagraxofusp Yields Deep Responses as Frontline BPDCN Therapy

Targeted Oncology Staff
June 10th 2025
Article

During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with blastic plasmacytoid dendritic cell neoplasm.

Read More